priors.science/reviews/rheumatoid-arthritis-targeted-therapy

Rheumatoid Arthritis Targeted Therapy

The current evidence on 6 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

6claims tracked
97primary papers reviewed
5 Jun 2026latest evidence review
Weeklyre-scored against new papers
0 Established · 5 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableTNF inhibitors improve response and slow radiographic progression in methotrexate-inadequate rheumatoid arthritisTNF BiologicsLikely83%20
StableJAK inhibitors match biologic disease-modifying antirheumatic drugs for remission in rheumatoid arthritis, given orallyJAK InhibitorsLikely79%10
StableTreat-to-target strategy improves outcomes versus routine care in rheumatoid arthritisT2T StrategyLikely79%20
StableInterleukin-6 receptor inhibitors achieve responses in rheumatoid arthritis, tocilizumab superior to adalimumabNon TNF BiologicsLikely76%20
StableAbatacept and rituximab match TNF inhibitors in rheumatoid arthritisNon TNF BiologicsLikely73%20
StableTofacitinib cardiovascular and malignancy safety signal reflects a JAK class effectJAK InhibitorsUncertain45%10
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic